Byung‐Ik Kim

Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial

Y. Chao, Jung-Hwan Yoon, Y. Chung, 2013, International journal of cancer.

Twenty‐four‐week clevudine therapy showed potent and sustained antiviral activity in HBeAg‐positive chronic hepatitis B

Joong-Won Park, S. Paik, Y. Chung, 2007, Hepatology.

Clevudine is highly efficacious in hepatitis B e antigen‐negative chronic hepatitis B with durable off‐therapy viral suppression

Joong-Won Park, K. Koh, Y. Chung, 2007, Hepatology.

The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add‐on lamivudine combination treatment

Y. Cho, C. Sohn, J. Park, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy

K. Koh, S. Paik, Y. Chung, 2011, Journal of Gastroenterology.

Genetic predisposition of hand‐foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma

E. Shin, H. Lee, S. Bae, 2013, Cancer.